Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States and the leading cause of cervical cancer. The Food and Drug Administration approved the first human papillomavirus vaccine and has recommended routine vaccination of 11 to 12 year old girls with catch-up vaccination for females 13 to 26 years of age. This primary prevention tool for cervical cancer could significantly reduce cervical cancer, but broad vaccination coverage will be required. Health care providers are in a position to educate parents and teens about the benefits of receiving the recommended HPV vaccine. Mandating the HPV vaccine can be effective in increasing vaccine rates, reducing disease disparities, and decreasing rates of cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1527154410370368 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proteomic Profiling of Potential E6AP Substrates via Ubiquitin-based Photo-Crosslinking Assisted Affinity Enrichment.
Chembiochem
January 2025
University of Konstanz, Department of Chemistry, Universitaetsstrasse 10, 78457, Konstanz, GERMANY.
The ubiquitin (Ub) ligase E6AP, which is encoded by the UBE3A gene, has been associated with several human diseases including cervical cancer and Angelman syndrome, a neurodevelopmental disorder. Yet, our knowledge about disease-relevant substrates of E6AP is still limited. The formation of a thioester complex between Ub and the catalytic Cys residue of E6AP represents an essential intermediate step in E6AP-mediated ubiquitination.
View Article and Find Full Text PDFThe Prognostic Value of Sarcopenia in Clinical Outcomes in Cervical Cancer: A Systematic Review and Meta-Analysis.
J Cachexia Sarcopenia Muscle
February 2025
Department of Clinical Nutrition, Peking Union Medical College Hospital, Beijing, China.
Background: Sarcopenia is a condition characterized by inadequate muscle and function decline and is often associated with ageing and cancer. It is established that sarcopenia and muscle loss occurred during treatment are associated with the clinical outcomes of patients with cancer. This systematic review and meta-analysis aims to evaluate the association between sarcopenia at pretreatment and during treatment and overall survival or disease progression in patients with cervical cancer.
View Article and Find Full Text PDFThe Clinical Characteristics and Treatment Outcomes of Mesonephric Tumours of the Uterine Cervix: A Systematic Review and Proposal of Embryologically-Oriented Surgical Resection.
J Clin Med
December 2024
Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9DU, UK.
: Cervical mesonephric adenocarcinomas (MNACs) are among the rarest neoplasms of the female genital tract. Unlike the majority of cervical cancers, which are predominantly squamous in origin and strongly associated with HPV seropositivity, MNACs are distinct in both histology and pathophysiology. Despite their unique characteristics, MNACs have historically been managed in parallel with squamous cell carcinomas, resulting in a lack of optimised, evidence-based treatment protocols.
View Article and Find Full Text PDFAlthough grade is a well-recognised prognostic factor for endometrioid endometrial cancer (EEC), in more studies grade 1 (G1) and grade 2 (G2) EEC are combined and compared together with grade 3 (G3) tumours. The aim of our study is to separately investigate the outcomes, prognostic factors and recurrence patterns of G2 EEC and whether the differentiation between G1 and G2 EEC is clinically useful. we retrospectively reviewed 523 patients with EEC treated with primary surgery over a decade (March 2010-January 2020) at Oxford University Hospitals NHS Trust, focusing on those with G2 disease.
View Article and Find Full Text PDFThe Effect of Postoperative Sepsis on 1-Year Mortality and Cancer Recurrence Following Transhiatal Esophagectomy for Esophageal-Gastric Junction Adenocarcinomas: A Retrospective Observational Study.
Cancers (Basel)
January 2025
Department of Anesthesiology and Critical Care, Paoli-Calmettes Institute, 13009 Marseille, France.
Introduction: Transhiatal esophagectomy (THE) is used for specific gastroesophageal junction adenocarcinomas. THE is a high-risk surgical procedure. We aimed to assess the impact of postoperative sepsis (sepsis or septic shock) on the 1-year mortality after THE and to determine the risk factors associated with these outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!